Pioglitazone

Generic Name: Pioglitazone

Brand Names: Actoplus Met, Actos, Duetact, Incresync, Oseni, Tandemact, Pioglitazone Accord, Pioglitazone Actavis

Drug Type: Small Molecule

Chemical Formula: C_₁₉H_₂₀N_₂O_₃S

CAS Number: 111025-46-8

Unique Ingredient Identifier: X4OV71U42S

Background: Pioglitazone is an antihyperglycemic used as an adjunct to diet, exercise, and other antidiabetic medications to manage type 2 diabetes mellitus. It is administered as a racemic mixture, though there is no pharmacologic difference between the enantiomers and they appear to interconvert in vivo with little consequence. The thiazolidinedione class of medications, which also includes rosiglitazone and troglitazone, exerts its pharmacological effect primarily by promoting insulin sensitivity and the improved uptake of blood glucose via agonism at the peroxisome proliferator-activated receptor-gamma (PPARγ). PPARs are ligand-activated transcription factors that are involved in the expression of more than 100 genes and affect numerous metabolic processes, most notably lipid and glucose homeostasis.

Thiazolidinediones, including pioglitazone, have fallen out of favor in recent years due to the presence of multiple adverse effects and warnings regarding their use (e.g. congestive heart failure, bladder cancer) and the availability of safer and more effective alternatives for patients with type 2 diabetes mellitus.

Indication: Pioglitazone is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. It is also available in combination with metformin, glimepiride, or alogliptin for the same indication.

Associated Conditions: Diabetes, Diabetic Neuropathies, Type 2 Diabetes Mellitus

Associated Therapies: -

Clinical Trials

Insulin Resistance in Non-alcoholic Fatty Liver Disease

Not Applicable

Terminated

Conditions: Fatty Liver

Interventions: Drug: placebo
Drug: fenofibrate
Drug: pioglitazone

First Posted Date: 2011-02-04

Last Posted Date: 2017-08-17

Lead Sponsor: VA Office of Research and Development

Target Recruit Count: 11

Registration Number: NCT01289639

Locations: 🇺🇸
VA Puget Sound Health Care System, Seattle, Seattle, Washington, United States

Efficacy and Safety of Alogliptin in Participants With Type 2 Diabetes

Phase 3

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: Placebo to alogliptin
Drug: Alogliptin
Drug: Metformin
Drug: Pioglitazone

First Posted Date: 2011-02-03

Last Posted Date: 2013-03-22

Lead Sponsor: Takeda

Target Recruit Count: 506

Registration Number: NCT01289119

A Randomized, Double-Blind, Comparator- and Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of MSDC-0602 in Type 2 Diabetic Patients

Phase 2

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: MSDC-0602 100 mg
Drug: Placebo
Drug: MSDC-0602 250 mg
Drug: Pioglitazone

First Posted Date: 2011-01-21

Last Posted Date: 2014-04-14

Lead Sponsor: Metabolic Solutions Development Company

Target Recruit Count: 129

Registration Number: NCT01280695

Pioglitazone in Early Parkinson's Disease

Phase 2

Completed

Conditions: Parkinson's Disease

Interventions: Drug: Pioglitazone
Drug: placebo

First Posted Date: 2011-01-20

Last Posted Date: 2015-10-14

Lead Sponsor: University of Rochester

Target Recruit Count: 210

Registration Number: NCT01280123

Locations: 🇺🇸
University of Southern California, Los Angeles, California, United States
🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States
🇺🇸
The Parkinson's & Movement Disorder Institute, Fountain Valley, California, United States

and more 35 locations